    Charles Dadswell | Illumina , Inc. | ZoomInfo.com


Charles Dadswell SVP and General Counsel | Management Team



































   
Sign In  Contact Us Select Country




Areas of Interest
Techniques
Systems
Products & Services
Informatics
Science & Education
Company
Support
 












About Us

Careers
News Center
Investor Information
Contact Us
Legal
Events
Video Hub
Partner Programs
iHope
Doing Business with Illumina



Overview

Management Team 


Fact Sheet


Corporate Citizenship


More





 Questions















About Us
            
        /Management Team 
            
        	/Charles Dadswell




Management Team








Management Team









Charles Dadswell
 Senior Vice President & General Counsel
Charles (Chuck) Dadswell is Senior Vice President and General Counsel of Illumina, where he has worldwide responsibility for all legal and intellectual property matters and is also Illumina's code of ethics compliance officer.
Before joining Illumina, Dadswell was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. He was previously General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company, and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline.
Dadswell received an LL.M. in patent law and trade regulation from The George Washington University Law School, a J.D. from Thomas M. Cooley Law School and a B.S. in Pharmacy from Ferris State University.

 < Prev | Next >


 















 
Management Team Fact Sheet
 






















Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version












 


Charles Dadswell's Phone Number, Email, Address - Spokeo





















































CONTACT US



{{vm.userEmail}}








{{dropdown_item.text}}













{{dropdown_item.text}}






{{dropdown_item.text | uppercase}}




















{{search_results_type}}
Results








Recent



{{history.title}}




Example Searches



John Smith



email@example.com



123 Main St, Pasadena, CA



(626) 555-5555



John Smith, Pasadena, CA






Search filters




First Name



Middle Name



Last Name





Age


{{ages}}
+






State


All States




City





Phone number



Email address





Relative First name



Relative Last name





SEARCH










Show Basic Search




Show Advanced Search



























 












Browse locationsCalifornia(4)Michigan(2)North Carolina(3)Ohio(2)South Carolina(1)







No results found for {{vm.NameSearch.search.display_name}}
with your specific filters:
{{filter}}
Try a more general search, or view similar matches below.






Home








People








Last Name (D)








Charles Dadswell






Charles DadswellCharles Dadswell found in California, North Carolina and 3 other states.



Browse locationsCalifornia(4)Michigan(2)North Carolina(3)Ohio(2)South Carolina(1)










Person


Charles
W
Dadswell, age 81



Locations

Hartsville,
SC



Relatives

Dianne

Dadswell


Staci

Dadswell


Peggy

Dadswell



Includes






SEE RESULTS









Person


Charles
E
Dadswell, age 59

Dadswell Dadswell


Locations

La Jolla,
CA


Cary,
NC


Holt,
MI


Wyoming,
MI


Grand Rapids,
MI



Relatives

F

Charles


R

Charles


T

Charles



Includes






SEE RESULTS









Person


Charles
E
Dadswell, age 81

Charle Dadswell


Locations

Holt,
MI


Cary,
NC


Chapel Hill,
NC


Cincinnati,
OH


Wyoming,
MI



Relatives

Nicholas

Dadswell


Patricia

Dadswell


Barbara

Dadswell


Judy

Dadswell



Includes






SEE RESULTS









Person


Charles

Dadswell, age 45



Locations

Cary,
NC



Relatives

Nicholas

Dadswell


Patricia

Dadswell


Barbara

Dadswell


Charle

Dadswell


Judy

Dadswell



Includes






SEE RESULTS









Person


Charles

Dadswell




Locations

Redwood City,
CA



Relatives
--


Includes






SEE RESULTS









Person


Charles

Dadswell




Locations

San Diego,
CA



Relatives
--


Includes






SEE RESULTS









Person


Charles

Dadswell




Locations

San Diego,
CA



Relatives
--


Includes






SEE RESULTS








Statistics for all
8
Charles Dadswell results:



65 yrs
Average age
50% are in their 80s, while the average age is 65.


$110k
average income
Our wealth data indicates income average is $110k.


100%
Caucasian
Our ethnicity data indicates the majority is Caucasian.


100%
Married
100% of these people are married, and 0% are single.





Business Records related to Charles Dadswell:




Charles Dadswell


Title:
General Counsel


Company:
Biodelivery Sciences International, Inc


CoWorkers:
Al Medwar, Dorothy Albin, Rita Bobo, Mark Salyer, Ken Schupp






Facebook

Twitter

Google Plus

YouTube

LinkedIn



About
Careers
Affiliates
Blog
Privacy
Terms
Contact
FAQs

More



People Search
email lookup
reverse phone lookup
ADDRESS LOOKUP
DIRECTORY



Spokeo is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to make decisions about employment, tenant screening, or any purpose covered by the FCRA.
Copyright © 2006-2017 Spokeo, Inc.























Charles Dadswell, Illumina Inc: Profile & Biography - Bloomberg


































































  




























Feedback





Charles Dadswell

Senior VP/Secretary/Gen Counsel,
Illumina Inc






Career History




Senior VP/Secretary/Gen Counsel
Illumina Inc, 4/2013-PRESENT


VP/Dir:Global/General Counsel
Biomerieux Inc, UNKNOWN-4/2013


Dir:Contract Mgmt/Gen Cnsl
Biodelivery Sciences International Inc, 1/2008-UNKNOWN


Vice President
Glaxosmithkline PLC, FORMER


General Counsel
Glaxo Wellcome PLC, FORMER


General Counsel
Glaxo Inc, FORMER


Show More









Website:
www.illumina.com






Corporate Information
Address:

5200 Illumina Way
San Diego, CA 92122
United States


Phone:
1-858-202-4500


Fax:
1-858-202-4766


Web url:
www.illumina.com











From The Web












Personal Information



Education



George Washington University Law School
LLM


Ferris State University
Bachelor's Degree


Thomas M Cooley Law School
JD


Show More








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data


































ILMN Charles E. Dadswell Insider Trades for Illumina Inc.


































Bulletin






Investor Alert







New York Markets Open in:



Market Snapshot
Analyst Ratings


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Illumina Inc.

                  NASDAQ: ILMN
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Illumina Inc.



Before the Bell
 --Quotes are delayed by 20 min
Jul 28, 2017, 8:03 a.m.


ILMN

/quotes/zigman/83650/composite


$
174.50




Change

+0.17
-1.02%

Volume
Volume 301
Quotes are delayed by 20 min








/quotes/zigman/83650/composite
Previous close

$
			176.30
		


$
				174.33
			
Change

-1.97
-1.12%





Day low
Day high
$173.01
$177.80










52 week low
52 week high

            $119.37
        

            $189.48
        


















Insider Activity


Individual




Charles E. Dadswell



Mr. Charles E. Dadswell is Secretary, Senior Vice President & General Counsel at Illumina, Inc.
Mr. Dadswell was previously employed as Vice President & General Counsel by bioMerieux, Inc., General Counsel by BioDelivery Sciences International, Inc., a Principal by Glaxo Wellcome, Inc., and Vice President-US Intellectual Property by GlaxoSmithKline, Inc.
He received his undergraduate degree from Ferris State University (Michigan), a graduate degree from The Thomas M. Cooley Law School, and a graduate degree from George Washington University Law School.



Transactions


Date
Shares
Transaction
Value





07/03/2017
145


 
Disposition at $174.24 per share.


25,265


06/05/2017
145


 
Disposition at $184.75 per share.


26,789


05/03/2017
1,609


 
Disposition at $187.07 per share.


300,996


04/24/2017
979


 
Derivative/Non-derivative trans. at $180.2 per share.


176,416


02/15/2017
4,691


 
Derivative/Non-derivative trans. at $163.29 per share.


765,994


02/15/2017
3,516


 
Award at $0 per share.


0


02/15/2017
7,032


 
Derivative/Non-derivative trans. at $0 per share.


0


02/06/2017
572


 
Disposition at $161.26 per share.


92,241


01/30/2017
256


 
Derivative/Non-derivative trans. at $159.28 per share.


40,776


01/10/2017
116


 
Disposition at $161.6 per share.


18,746


12/02/2016
2,542


 
Award at $0 per share.


0


11/07/2016
352


 
Derivative/Non-derivative trans. at $137.08 per share.


48,253


10/04/2016
116


 
Disposition at $182.38 per share.


21,157


09/06/2016
116


 
Disposition at $168.01 per share.


19,490


08/04/2016
116


 
Disposition at $164.63 per share.


19,098


07/27/2016
8,632


 
Disposition at $155 per share.


1,337,960


04/22/2016
979


 
Derivative/Non-derivative trans. at $143.59 per share.


140,575


04/04/2016
1,360


 
Disposition at $169.1 per share.


229,976


04/04/2016
3,751


 
Disposition at $167.99 per share.


630,131


04/04/2016
3,271


 
Disposition at $167.08 per share.


546,519


03/08/2016
3,002


 
Disposition at $156.12 per share.


468,673


03/08/2016
5,264


 
Disposition at $155.36 per share.


817,816


03/07/2016
116


 
Disposition at $155 per share.


17,980


03/03/2016
25,577


 
Derivative/Non-derivative trans. at $157.45 per share.


4,027,099


03/03/2016
16,875


 
Award at $0 per share.


0


03/03/2016
33,750


 
Derivative/Non-derivative trans. at $0 per share.


0


01/29/2016
255


 
Derivative/Non-derivative trans. at $157.95 per share.


40,278


12/28/2015
168


 
Disposition at $188.63 per share.


31,690


12/08/2015
1,376


 
Award at $0 per share.


0


11/27/2015
169


 
Disposition at $180.72 per share.


30,542


11/05/2015
125


 
Derivative/Non-derivative trans. at $154.75 per share.


19,344


11/03/2015
158


 
Disposition at $150 per share.


23,700


09/28/2015
157


 
Disposition at $173.2 per share.


27,193


08/27/2015
163


 
Disposition at $198.81 per share.


32,407


07/27/2015
167


 
Disposition at $218.92 per share.


36,560


06/29/2015
160


 
Disposition at $215.63 per share.


34,501


05/27/2015
170


 
Disposition at $206.62 per share.


35,126


04/30/2015
129


 
Disposition at $185.88 per share.


23,979


04/27/2015
34


 
Disposition at $190.04 per share.


6,462


04/22/2015
705


 
Derivative/Non-derivative trans. at $190.04 per share.


133,979


03/27/2015
99


 
Disposition at $184.62 per share.


18,278


02/02/2015
65


 



8,888


01/29/2015
247


 
Derivative/Non-derivative trans. at $200 per share.


49,400


01/27/2015
224


 
Disposition at $198.9 per share.


44,554


12/29/2014
146


 
Disposition at $188.2 per share.


27,478


12/05/2014
1,317


 
Award at $0 per share.


0


11/28/2014
150


 
Disposition at $192.76 per share.


28,914


10/27/2014
147


 
Disposition at $189.84 per share.


27,907


09/29/2014
147


 
Disposition at $163.73 per share.


24,069


08/27/2014
151


 
Disposition at $180.12 per share.


27,199


07/28/2014
144


 
Disposition at $171 per share.


24,624


06/27/2014
192


 
Disposition at $171.44 per share.


32,917


04/22/2014
704


 
Derivative/Non-derivative trans. at $147.98 per share.


104,178


01/29/2014
2,344


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Jay T. Flatley 
Executive Chairman




Mr. Francis A. deSouza 
President, Chief Executive Officer & Director




Mr. Sam A. Samad 
Chief Financial Officer & Senior Vice President




Dr. Mostafa  Ronaghi 
Chief Technology Officer & Senior Vice President




Mr. Norman  Fjeldheim 
Chief Information Officer




Mr. Mark  Van Oene 
Chief Commercial Officer




Dr. Garret  Hampton 
Executive Vice President-Clinical Genomics




Ms. Paula  Dowdy 
Senior Vice President




Dr. Gregory F. Heath 
Senior Vice President & GM-Diagnostics




Mr. Ostadan  Omead 
Executive VP-Operations, Products & Strategy




Mr. Sanjay  Chikarmane 
Senior VP & General Manager-Enterprise Informatics




Dr. John Wendell Thompson 
Director




Dr. Bryan E. Roberts 
Director




Ms. Caroline D. Dorsa 
Director




Mr. Philip W. Schiller 
Director




Dr. Frances Hamilton Arnold 
Director




Ms. Rebecca  Chambers 
Vice President-Investor Relations & Treasury




Mr. Michael  Bouchard 
Chief Accounting Officer & Vice President




Mr. Charles E. Dadswell 
Secretary, Senior Vice President & General Counsel




Mr. Roy A. Whitfield 
Independent Director




Mr. Arthur Blaine Bowman 
Independent Director




Dr. Robert S. Epstein 
Independent Director




Ms. Karin  Eastham 
Independent Director




Mr. Daniel Mark Bradbury 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/65801738/composite TLT+1.11%


/quotes/zigman/59386294/composite JNUG-5.94%


X




Powered by














Log In




8:22 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Pre


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
8:22aAlexion Pharmaceuticals upgraded to outperform from perform at Oppenheimer
8:21aMerck says it issued conservative guidance due to recovery from cyber attack in late June
8:19aNuVasive downgraded to neutral from outperform at Baird
8:19aA provocative new analysis suggests you don’t have to take all your antibiotics after all
8:18aWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
8:18aScaramucci says Trump’s love of cheeseburgers shows he’s not an elitist — 5 ways rich people act humble
8:17aTeekay Offshore Partners downgraded to market perform from outperform at Raymond James
8:17a5 weird things I found out about America in my first 24 hours 
8:17aElectronic Arts shares slide 3% as outlook falls short
8:16aIntel stock price target raised to $41 from $39 at Stifel Nicolaus
8:15aUPS stock price target raised to $103 from $100 at Stifel Nicolaus
8:15aMeet the ‘Hamilton’ actors who fly cross-country and play up to 18 roles in the hit show
8:15aExpedia stock price target raised to $160 from $135 at Stifel Nicolaus
8:14aAmazon stock price target raised to $1,100 from $1,075 at Stifel Nicolaus
8:13aHawaiian Holdings upgraded to hold from sell at Stifel Nicolaus
8:13aStarbucks stock price target cut to $58 from $66 at Stifel Nicolaus
8:13aTTM Technologies downgraded to hold from buy at Stifel Nicolaus
8:12aThis fund strategist says there’s at least one way companies can survive Amazon’s onslaught
8:12aStarbucks downgraded to hold from buy at Stifel Nicolaus
8:12aA quarter of S&P 500’s 2017 climb due to five stocks (yes, those five)
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15
























































Dadswell, Charles E 5200 Illumina Way San Diego, CA Lawyers - MapQuest







































































































    Dadswell, Charles E
  

5200 Illumina Way

San Diego
CA
92122




 Reviews



(858) 202-4500

        Menu & Reservations
      



            Make Reservations 




            Order Online
          

            Tickets
          




          Tickets
        


        See Availability
      





      Nearby
    


      Directions
    


    {{::location.tagLine.value.text}}
  



Sponsored Topics








































See a problem?
Let us know!






















Legal






Help

















































Paired Ends: Charles Dadswell | GenomeWeb



















Skip to main content



 







 





 









RSS Feeds
Twitter
LinkedIn
 





 







Log in




Join now


 






Business & PolicyBusiness News
Research Funding
Policy & Legislation
Regulatory News
Reimbursement

TechnologyMicroarrays & Multiplexing
PCR
Informatics
Sequencing
Mass Spec
Sample Prep
Gene Silencing/Gene Editing

ResearchGenetic Research
Gene Expression Research
Epigenetics Research
Proteomics & Protein Research
Cell Biology Research

DiagnosticsMolecular Diagnostics
Companion Diagnostics
Biomarker Discovery & Validation
Drug Discovery & Development
Clinical Sequencing
Clinical Proteomics

Disease AreasCancer
Infectious Disease
Cardiovascular Disease
Neurological & Psychological Disease
Metabolic Disease
Autoimmune Disease
Inherited Disease
Reproductive Health

Applied Markets
ResourcesWebinars
White Papers
The Scan
Career Blog
Job Listings
New Products
People in the News
Conferences & Events


Main menu 






Enter your keywords 





 





Home » Paired Ends: Charles Dadswell 

















Paired Ends: Charles Dadswell

Apr 23, 2013


Premium 



Illumina has named Charles Dadswell senior vice president and general counsel, replacing Christian Cabou, who has retired. Dadswell will be responsible for all legal and intellectual property matters and will also serve as secretary to Illumina's board of directors. He joins Illumina from BioMérieux, where he served as vice president and general counsel for North and Latin America and corporate director of global intellectual property.



Get the full story with GenomeWeb Premium
Only $95 for the first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
        Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?
Register for Free Content
You can still register for access to our free content.
        
 













 












Breaking News 

  



Fluidigm, Ascendas Genomics Ink MDx Development Pact in China  








Cancer Dependency Maps Developed by Two Research Teams  








Error-Prone DNA Repair Implicated in Analysis of Cancer Mutation Signature Clusters  








Ancient Genome Sequences Point to Canaanite Ancestry in Present-Day Lebanese Population  








Qiagen Q2 Revenues Grow 4 Percent; Firm Nudges Up Full-Year Guidance  








Biomatrica Gets CE-IVD Marks for Sample Collection Tubes  




 
 





 







The Scan 







Embryos Edited in US 

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.



 









True Blue 

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.



 









All the Plants 

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.



 









This Week in Nature 

In Nature this week: a Danish reference genome, and more.



 






 







Featured White Papers




 By SeraCare 
 Seraseq ctDNA: A Breakthrough QC Technology  

 By SeraCare 
 2 Tools for Overcoming Your Clinical Lab’s Toughest Quality Control Challenges  


 





 











 




What's Popular?



      In Clinical Sequencing    

  



Helix Launches Genomics Marketplace Hoping to Entice Consumers to Repeatedly Query DNA  








Quest Joins Growing Market for Expanded Carrier ScreeningPremium  








Stanford Team Launches SensOmics in China for Early Autism DiagnosticsPremium  




 
 





 





 












Sponsorships 





 





 





 





 





 





 









 






About us
Advertise
Contact
Jobs
Subscribe







Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved. 





 



















﻿







Reasons for Charles Dadswell’s Shares Unload of Illumina, Inc. (NASDAQ:ILMN)’s Stock – Octafinance
























































 








Friday, 28 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can’t Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Reasons for Charles Dadswell’s Shares Unload of Illumina, Inc. (NASDAQ:ILMN)’s Stock


04/29/2015  by OctaStaff 
			in Blue Chips, Insider News 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Reasons for Charles Dadswell’s Shares Unload of Illumina, Inc. (NASDAQ:ILMN)’s Stock and is was published by Octafinance.com at http://www.octafinance.com/reasons-for-charles-dadswells-shares-unload-of-illumina-inc-nasdaqilmns-stock/33848/.CaptchaSubmit
Charles Dadswell Insider Sell Transaction
 Mr. Charles Dadswell, the present Sr VP & General Counsel at Illumina, Inc. (NASDAQ:ILMN)  174.33 -1.97 -1.12% has not a long ago been connected with an open market trade of 34 shares of the -listed Illumina Inc, valued at $190.0 per share. The total stocks unloaded with a value of of $6,461 US Dollars. In the last month, he also sold 99 shares worth approximately $18,277 USD. Charles Dadswell now has in hand 0.03% of the Company’s stock market cap with ownership of 41,951 shares. 
Illumina Inc Stock Rating, Sentiment and Fundamentals
 And his view is not unjustified – twenty six top equity analysts covering Illumina Inc believe that the earnings-per-share will be $3.43 in 2015, giving it a price to earnings ratio of 53.75 and a growth rate YOY not better than 22.81%. Additionally, the market agrees with his sell. According to the innovative company Psychsignal, the Sentiment Index is 0.49. 






Rating & SentimentPsychSignal Social:SELLAnalysts Rating:BUYHedge Funds Sentiment:BUY




Stock FundamentalsEarnings + FCF Trend:BUYSector/Industry Macro:BULLISHValuation Models:-


 


Technical AnalysisST Trend:DOWNMT Trend:DOWNLT Trend:UP




OctaFinance Rating*:SELL


* Read How Our Stock Ratings System Works








 Our analysts rate Illumina Inc “Sell”, not just because of Charles Dadswell’s informed stock sell but also because our time momentum model says so. Illumina Inc’s stock chart indicates it has decreased 3.62% in the last 125 days and the steady and strong down trend is expected to continue. 
Price Chart of Illumina NASDAQ:ILMN Stock
 
Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations
Hedge Funds Ownership
 Data gathered from SEC 13F filings, show that 506 hedge funds and institutional investors have shares of Illumina Inc. The institutional ownership of the company’s stock in Q4 2014 is extremely high, at 92.01% of the shares outstanding. They decreased by 1.75 million the total shares they hold. As of that quarter these investment managers owned 132.16 million shares. A total of 39 funds closed their positions in Illumina Inc and 146 reduced their holdings. There were 86 funds that created new positions and 212 funds that added to their positions. 
 22 hedge funds are super bullish the stock and have it in their Top 10. They are: Rosenblum Silverman Sutton S F Inc Ca, Viking Global Investors Lp, Wellington Shields & Co. Llc, Bender Robert & Associates, Duquesne Family Office Llc, Baillie Gifford & Co, Bennett Lawrence Management L L C Ny, Cookson Peirce & Co Inc, Cubist Systematic Strategies Llc, De Burlo Group Inc.
  Rosenblum Silverman Sutton S F Inc Ca is the most positive institutional investor on Illumina Inc, with ownership of 69,223 shares as of Q4 2014 for 5.50% of the fund’s portfolio. Andreas Halvorsen’s Viking Global Investors Lp is another positive institutional investor having 8.29 million shares of the company or 7.03% of their stocks portfolio. The stock is also 3.84% of the fund’s AUM. Moreover Wellington Shields & Co. Llc have 15.89% of their stock portfolio invested in the stock for 150,919 shares. The California-based fund Bender Robert & Associates revealed it had acquired a stake worth 7.90% of the fund’s stock portfolio in Illumina Inc. Stanley Druckenmiller’s Duquesne Family Office Llc is also very upbeat about the California-based company, with ownership of 410,100 shares or 7.42% of their stock portfolio.
Illumina NASDAQ:ILMN Company Profile
Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. In July 2014, the Company acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.
 Illumina Inc has 3700 employees. Currently its market cap is: $26.51 billion and it has 144.30 million shares outstanding. Currently there are 95.14% shareholders and the institutional ownership is 95.14%. Illumina Inc was incorporated in Delaware on 2000-05-16. The stock closed at $184.38 yesterday and it had average 2 days volume of 429957 shares. It is up from the 30 days average shares volume of 391596. Illumina Inc has a 52w low of $128.40 and a 52weeks high of $213.30. The stock price is above the 200 days Simple moving average. Illumina Inc last issued its quarterly earnings report on 04/21/2015. The company reported 0.91 EPS for the quarter, above the consensus estimate of 0.72 by 0.19. The company had a revenue of 512.38 million for 12/28/2014 and 480.63 million for 9/28/2014. Therefore, the revenue was 31.75 million up.
* The sale was made pursuant to a 10b5-1 plan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.







 
Tagged: Charles DadswellIllumina - (NASDAQ:ILMN)



Illumina, Inc. (NASDAQ:ILMN)’s director Blaine Bowman Unloaded 3000 shares of the Company Ben Plummer Unloaded $15,798 Worth of Datawatch Corporation (NASDAQ:DWCH) Stock 



 





Free Email Newsletter
    Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:







Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking CrisisAre US – Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?—put volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs’ Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?



















